Trial Profile
A registrational trial of AAVrh74.MHCK7.micro-Dystrophin gene therapy for the treatment of Duchenne muscular dystrophy
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 10 Oct 2018
Price :
$35
*
At a glance
- Drugs Delandistrogene moxeparvovec (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- 10 Oct 2018 New trial record